Amneal Pharmaceuticals, Inc. reported Q4 2025 net revenue of $814 million and full year 2025 net revenue of $3.02 billion, with GAAP net income of $35 million and $72 million respectively. The company provided 2026 guidance of $3.05 to $3.15 billion in net revenue and $720 to $760 million in Adjusted EBITDA, and will host a conference call at 8:30 am ET on February 27, 2026.
Key takeaways
Q4 2025 Net Revenue $814 million, up 11% from $731 million in Q4 2024
Q4 2025 GAAP Net Income $35 million; Adjusted EBITDA $175 million
Full Year 2025 Net Revenue $3.02 billion, up 8% from $2.79 billion in 2024
Full Year 2025 GAAP Net Income $72 million; Adjusted EBITDA $688 million
2026 Guidance: Net Revenue $3.05-$3.15 billion; Adjusted EBITDA $720-$760 million
Conference call at 8:30 am ET February 27, 2026 via https://investors.amneal.com